Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 651 across all filing types
Latest filing 2020-07-24 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and contractual relationships (such as pledges) of major shareholders. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2020-07-24 Korean
투자판단관련주요경영사항(알츠하이머병 치료제로서 GV 1001의 국내 제2상 임상시험 결과)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (GemVax) submitted to the Korea Exchange (KRX). It details the results of a Phase 2 clinical trial for a drug (GV1001). While it contains clinical trial data, it is structured as a 'Major Management Matter' disclosure (a standard regulatory filing format in Korea) rather than a standalone audit report or a scientific publication. Since it does not fit into specific categories like 10-K, ER, or CT, and is a formal regulatory disclosure of material information, it falls under the 'Regulatory Filings' category.
2020-07-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and pledge agreements of major shareholders. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2020-06-04 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, special relationships, and major contracts (pledges, loans) by a major shareholder (Gem & Company) and related parties in the company GemVax & KAEL. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2020-05-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when an executive or a major shareholder (in this case, Gem & Company) changes their shareholding position in a listed company (GemVax & Kael). This type of filing is classified as a 'Director's Dealing' or 'Insider Trading' report, which falls under the 'DIRS' category in the provided schema.
2020-05-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (Korea). This type of filing is specifically used to report insider transactions (share purchases or sales) by company directors or major shareholders. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2020-05-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.